Product
Positive control
Aliases
Shingrix®
3 clinical trials
3 indications
Indication
Herpes ZosterIndication
Respiratory Syncytial VirusIndication
Respiratory Syncytial Virus InfectionClinical trial
A Phase I, Single Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase II, Single Center, Randomized, Blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and OlderStatus: Not yet recruiting, Estimated PCD: 2025-02-01